Antihypertensive treatment in Germany, subjected to a cost-effectiveness analysis.
German physicians are increasingly adopting national and international recommendations on the promotion of non-pharmacological treatment of elevated blood pressure. This reflects a greater sensibility to the advantages and disadvantages of antihypertensive drugs versus dietary means. Furthermore, the rapid growth of health expenditure is a central issue in many policy decisions. Increasingly, the use of cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) is being advocated as a possible means of making the medical care system more efficient. We report an analysis of the value of treating hypertension in Germany-West.
Laaser
U
U
University of Bielefeld, W. Germany.
Wenzel
H
H
D000368:Aged; D002561:Cerebrovascular Disorders / Q000453:epidemiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D005260:Female; D005860:Germany, West / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000191:economics* / Q000453:epidemiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control